Clinical Trial Recruitment Cost: How Much Sponsors Pay Per Patient

A 2018 analysis of FDA pivotal trials found a median cost of $41,117 per enrolled patient [1]. Between the 25th and 75th percentiles, the range ran from $31,802 to $82,362 [1]. A separate federal cost study put total patient recruitment spending at 1.7% to 2.7% of a trial's overall budget [2]. Vendor marketing puts it at 20% to 30%.

Clinical trial recruitment cost per patient gets quoted constantly but the numbers are rarely sourced. This article provides cited figures to give sponsors and CROs more accurate data. Every figure below traces to a named study, a federal report, or an industry estimate clearly labeled as unsourced.

Refero does not run recruitment campaigns. We vet and match the clinical research marketing agencies that do. What follows is written for the buyer who needs to check a vendor's quote against published data, not against a calculator's round number.

Clinical trial recruitment cost statistics at a glance

Every figure here is sourced in full at the foot of the page.

• Median per-patient cost across FDA pivotal trials approved in 2015 and 2016 was $41,117, with an interquartile range of $31,802 to $82,362 [1]
• Patient recruitment accounts for 1.7% to 2.7% of a trial's total budget, not the 20% to 30% often claimed [2]
• A single delay day costs roughly $40,000 in direct Phase II or III trial costs plus about $500,000 in foregone sales [3]
• Median centralized outreach cost per patient ranged from $143 in vaccine trials to $11,392 in immunology trials, a nearly 80-fold spread [4]
• Genitourinary oncology trials report screen failure rates near 20% to 30%, with a mean of 26% in Phase III prostate cancer trials [6]

What counts as clinical trial recruitment cost

Recruitment cost is everything a sponsor spends to find, contact, and screen candidates through to randomization: media buys, referral fees, call-center and coordinator time, and screening procedures run on every candidate, not only the ones who enroll. It is not the same number as the trial's total conduct cost, which adds monitoring, data management, and site overhead. Protocol complexity sets the ceiling before a single patient is contacted, and the enrollment-timeline data behind this budget shows why: a protocol that is hard to enroll is also expensive to enroll.

Clinical trial recruitment cost per patient: what the data shows

There is no single number for clinical trial recruitment cost per patient. The most detailed recent data on centralized outreach, a 2026 Tufts CSDD analysis of 32 studies, found median per-patient enrollment cost ranging from $143 in vaccine trials to $11,392 in immunology trials [4].

The same study found that social media and digital advertising (Facebook ads, Instagram, and Google ads) took an average of 64.7% of centralized outreach recruitment budgets [4]. If media spend is billed on top of a vendor's management fee, a quote that looks lower than a competitor's may simply be leaving out the largest line item.

Clinical trial cost by phase and therapeutic area

A 2014 federal cost study estimated average per-study cost at $3.8 million for Phase I, $13.35 million for Phase II, $19.89 million for Phase III, and $19.95 million for Phase IV [2]. A separate peer-reviewed analysis of FDA pivotal trials approved in 2015 and 2016 found a median direct trial cost of $19 million (IQR $12 million to $33 million), with cardiovascular trials averaging more than $157 million and oncology trials averaging $45.4 million [1]. A peer-reviewed breakdown of the same federal data by therapeutic area found Phase 2 costs from $7.0 million (cardiovascular) to $19.6 million (hematology) and Phase 3 costs from $11.5 million (dermatology) to $52.9 million (pain and anesthesia) [5]. Phase-level totals cover the whole trial, including monitoring and data management, so they are useful for sizing a program, not for pricing a recruitment contract.

Per-site and per-delay-day costs: the two numbers recruitment controls

Tufts Center for the Study of Drug Development estimates that one day of delay in a Phase II or III trial costs roughly $40,000 in direct trial costs plus about $500,000 in foregone sales [3]. Add the delay-day figure to the comparison and a slower, cheaper recruitment plan can cost more than a faster, pricier one. Site activation is commonly estimated at $20,000 to $25,000 per site, though that range traces to a 2008 enrollment model and a vendor conference citation rather than a published study, so treat it as directional.

Screen failure cost: the line item vendors rarely itemize

Every candidate who enters formal screening and fails it still consumed a referral fee, coordinator time, and screening procedures without producing an enrolled patient. In contemporary Phase II and III genitourinary oncology trials, screen failure rates ran roughly 20% to 30%, with a mean of 26% in Phase III prostate cancer trials [6]. The $1,200 to $2,000 per-failure figure that circulates online traces only to vendor blogs with no visible study behind it. Cost per randomized patient, not cost per referral, is the number worth comparing across quotes.

How recruitment vendors price their services

The structure decides who carries the financial risk of a high screen-failure rate. Media spend is often billed separately from the management fee; in one recent study roughly two-thirds of centralized outreach budgets went to social media and digital ads [4]. A sponsor who has not asked whether media is billed separately may be comparing two quotes that are not the same size.

Refero gets sponsors matched with agencies that fit their budget by screening candidates against published criteria before making an introduction.

How to choose a clinical trial recruitment vendor on cost

These questions surface numbers a vendor might not volunteer.

1. How is your fee structured: per referral, per screened candidate, per randomized patient, or a flat program fee? The answer decides who bears the cost when the screen-failure rate runs high.

2. Can you share your cost per randomized patient on a comparable protocol in this therapeutic area, not a cross-trial average? Published data shows close to an 80-fold spread by therapeutic area [4].

3. Is media spend billed separately from your management fee, and what is the split? In one recent study, roughly two-thirds of centralized outreach budgets went to social media and digital ads, so a fee-only quote can hide most of the real number [4].

4. What is included in your reported cost per patient: screening and site coordination, or media spend as well? Vendors and published studies define the term differently, and comparing quotes without a shared definition compares different numbers.

If you would rather not run that evaluation alone, Refero screens healthcare marketing and patient recruitment agencies against five published criteria and introduces up to three that fit your brief. It is free for buyers, and there is no obligation to hire anyone we introduce. Tell us what you need.

Frequently asked questions

How much does clinical trial recruitment cost per patient?

There is no single number. Centralized outreach data puts median cost per patient at $143 in vaccine trials and $11,392 in immunology trials, a spread of nearly 80 times [4]. The all-in cost of running a pivotal trial is far higher: a median of $41,117 per patient across FDA approvals in 2015 and 2016 [1].

How much does a clinical trial cost by phase?

A 2014 federal cost study estimated average per-study cost at $3.8 million for Phase I, $13.4 million for Phase II, $19.9 million for Phase III, and $20.0 million for Phase IV [2]. A separate analysis of pivotal trials found a median direct cost of $19 million (IQR $12 million to $33 million) [1].

Why does clinical trial recruitment cost vary so much by therapeutic area?

Cost tracks how hard eligible patients are to find. Vaccine trials draw from healthy volunteers ($143 median outreach cost per patient), while immunology and oncology trials need patients with a specific diagnosis, stage, or biomarker ($11,392 median) [4]. At the whole-trial level, cardiovascular pivotal trials averaged more than $157 million against a $19 million median across all areas [1].

What percentage of a clinical trial's budget goes to patient recruitment?

About 2%, based on the one government study that measured it. The 2014 federal cost analysis put patient recruitment at 1.7% to 2.7% of the overall trial budget [2]. The widely repeated 20% to 30% claim has no identifiable study behind it.

How do patient recruitment vendors price their services?

Most vendors use one of four structures: a fee per referral, per screened candidate, per randomized patient, or a flat program fee. The structure decides who absorbs screen-failure risk. Media spend is often billed separately from the management fee, so a fee-only quote can leave out most of the real number [4].

Sources

• Moore TJ, Zhang H, Anderson G, Alexander GC. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. JAMA Internal Medicine, 2018;178(11):1451-1457. Link
• Eastern Research Group, Inc., for the US Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. Examination of Clinical Trial Costs and Barriers for Drug Development. 2014. Link
• Smith ZP, DiMasi JA, Getz KA. New Estimates on the Cost of a Delay Day in Drug Development. Therapeutic Innovation & Regulatory Science, Tufts Center for the Study of Drug Development, 2024. Link
• Kim JY, Lamberti MJ, Do H. Measuring Centralized Patient Outreach Recruitment Strategies and their Costs in Clinical Trials. Therapeutic Innovation & Regulatory Science, 2026;60(5):1344-1351, Tufts Center for the Study of Drug Development. Link
• Sertkaya A, Wong HH, Jessup A, Beleche T. Key Cost Drivers of Pharmaceutical Clinical Trials in the United States. Clinical Trials, 2016;13(2):117-126. Link
• Wong SE, North SA, Sweeney CJ, Stockler MR, Sridhar SS. Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clinical Genitourinary Cancer, 2017. Link